Advertisement
Screener

LIPOCINE INC. (LPCN) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate

1.7 / 5 stars · 26/77 Roast Me

LIPOCINE INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate

LIPOCINE INC. (LPCN) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate of 84.91% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-10.

Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate · last filed 2026-03-10

  • LIPOCINE INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2024-03-31 was 97.41%, a 0.20% decline year-over-year.
  • LIPOCINE INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2023-03-31 was 97.61%, a 4.71% decline year-over-year.
  • LIPOCINE INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2022-03-31 was 102.43%, a 1.46% increase year-over-year.
  • LIPOCINE INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2021-03-31 was 100.96%, a 1.87% increase year-over-year.
  • LIPOCINE INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2025 was 84.91%, a 14.02% decline from fiscal 2024.
  • LIPOCINE INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2024 was 98.76%, a 0.21% decline from fiscal 2023.
  • LIPOCINE INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2023 was 98.97%, a 0.34% decline from fiscal 2022.
  • LIPOCINE INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2022 was 99.31%, a 2.81% decline from fiscal 2021.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 3 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 6 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 9 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 9 month as first filedShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 12 month
2025-12-3184.91%
10-K · filed 2026-03-10
2024-12-3198.76%
10-K · filed 2026-03-10
2024-03-3197.41%
10-Q · filed 2024-05-09
2023-12-3198.97%
10-K · filed 2025-03-13
2023-09-3098.97%
10-Q · filed 2023-11-08
2023-06-3098.97%
10-Q · filed 2023-08-10
2023-03-3197.61%
10-Q · filed 2024-05-09
2022-12-3199.31%
10-K · filed 2024-03-07
2022-09-30101.50%
10-Q · filed 2023-11-08
2022-06-30101.67%
10-Q · filed 2023-08-10
2022-03-31102.43%
10-Q · filed 2023-05-11
2021-12-31102.18%
10-K · filed 2023-03-10
2021-09-3095.52%
10-Q · filed 2022-11-09
101.68%
10-Q · filed 2021-11-10
2021-06-3095.52%
10-Q · filed 2022-08-08
2021-03-31100.96%
10-Q · filed 2022-05-09
2020-12-31100.32%
10-K · filed 2022-03-09
2020-09-3099.52%
10-Q · filed 2021-11-10
2020-06-3099.52%
10-Q · filed 2021-08-05
2020-03-3199.11%
10-Q · filed 2021-05-06
2019-12-3180.38%
10-K · filed 2021-03-11
2019-09-3080.38%
10-Q · filed 2020-11-10
2019-06-3079.13%
10-Q · filed 2020-08-06
2018-12-3183.56%
10-K · filed 2020-03-13
2018-09-3077.29%
10-Q · filed 2019-11-12
2018-06-3077.29%
10-Q · filed 2019-08-07
2017-12-3180.54%
10-K · filed 2019-03-06
2017-09-3085.56%
10-Q · filed 2018-11-07
2017-06-3085.56%
10-Q · filed 2018-08-07
2017-03-3182.70%
10-Q · filed 2017-05-08
2016-12-3184.26%
10-K · filed 2019-03-06
2016-09-3082.33%
10-Q · filed 2017-11-08
2016-06-3082.33%
10-Q · filed 2017-08-07
2016-03-3182.70%
10-Q · filed 2016-05-09
2015-12-3181.39%
10-K · filed 2018-03-12
2015-09-3080.95%
10-Q · filed 2016-11-08
81.20%
10-Q · filed 2015-11-12
2015-06-3080.95%
10-Q · filed 2016-08-09
2015-03-3170.00%
10-Q · filed 2015-05-07
2014-12-3176.30%
10-K · filed 2017-03-06
2014-09-3076.17%
10-Q · filed 2015-11-12
2014-06-3073.09%
10-Q · filed 2015-08-11
2014-03-3170.00%
10-Q · filed 2014-05-13
2013-12-3168.27%
10-K · filed 2015-03-11

Similar stocks

Stock NameCountryMarket CapPE Ratio
PALATIN TECHNOLOGIES INC (PTN)United States$0.017B-5.36
Allarity Therapeutics, Inc. (ALLR)United States$0.017B-1.66
Biofrontera Inc. (BFRI)United States$0.018B-2.13
Pasithea Therapeutics Corp. (KTTA)United States$0.017B-0.81
Rocket One Inc. (RKTO)United States$0.019B
Korsana Biosciences, Inc. (CYCN)United States$0.016B
Shuttle Pharmaceuticals Holdings, Inc. (SHPH)United States$0.019B-0.31
Citius Pharmaceuticals, Inc. (CTXR)United States$0.016B-133.06
Lantern Pharma Inc. (LTRN)United States$0.015B-2.87
Cellectar Biosciences, Inc. (CLRB)United States$0.020B-1.03